Cargando…
Pharmacodynamic Biomarkers for Emerging LRRK2 Therapeutics
Genetic studies have identified variants in the LRRK2 gene as important components of Parkinson’s disease (PD) pathobiology. Biochemical and emergent biomarker studies have coalesced around LRRK2 hyperactivation in disease. Therapeutics that diminish LRRK2 activity, either with small molecule kinase...
Autores principales: | Kelly, Kaela, West, Andrew B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7438883/ https://www.ncbi.nlm.nih.gov/pubmed/32903744 http://dx.doi.org/10.3389/fnins.2020.00807 |
Ejemplares similares
-
Exosome markers of LRRK2 kinase inhibition
por: Wang, Shijie, et al.
Publicado: (2020) -
The Emerging Functions of LRRK2 and Rab GTPases in the Endolysosomal System
por: Kuwahara, Tomoki, et al.
Publicado: (2020) -
A Critical LRRK at the Synapse? The Neurobiological Function and Pathophysiological Dysfunction of LRRK2
por: Kuhlmann, Naila, et al.
Publicado: (2020) -
Alterations in the LRRK2-Rab pathway in urinary extracellular vesicles as Parkinson’s disease and pharmacodynamic biomarkers
por: Taymans, Jean-Marc, et al.
Publicado: (2023) -
Synaptic function is modulated by LRRK2 and glutamate release is increased in cortical neurons of G2019S LRRK2 knock-in mice
por: Beccano-Kelly, Dayne A., et al.
Publicado: (2014)